Cancer drug development service company Imagen Therapeutics has moved its headquarters to Cheshire's Sci-Tech Daresbury science park, with plans to quadruple its workforce over the next few years.
Founded by former AstraZeneca cell biologists, the company is credited with the creation of the predictRx patient screening platform and the predictTx, designed to accelerate and de-risk drug development.
The move is backed by a grant from the Inward Investment Facilitation Fund (I2F2), part of the £75 million Liverpool City Region Business Growth Package.
CEO of Imagen Therapeutics Geoff Muckle (pictured) said: “Our expansion into Sci-Tech Daresbury marks a significant step in our growth journey. We started as a small assay development company, and our passion for implementing personalised oncology has driven our ambition to become a world-class research organisation that will support the acceleration of discovering new cancer treatments and cures.”
Initially, 15 staff will be based at the site’s Vanguard House with the numbers planned to grow to 60 eventually. Established in 2006, Sci-Tech Daresbury hosts the STFC Daresbury Laboratory, together with 150 high-tech companies.